Is Need Chemotherapy Titration During Acute Myeloid Leukemia Treatment?

Authors

  • Babak Abdolkarimi Assistant Professor of Pediatric Hematology-Oncology, Lorestan University of Medical Sciences, Khoramabad, Iran Author
  • Soheila Zareifar Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Mahdi Shahriari Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Mohamad Reza Bordbar Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran Author
  • Ali Amanat Assistant Professor of Pediatric infectious disease, Dr Alborzi Research center, Shiraz University of Medical Sciences, Shiraz, Iran Author

DOI:

https://doi.org/10.47363/JONRR/2021(2)131

Keywords:

Chemotherapy, Leukemia, Acute Myeloid

Abstract

Persistent marrow aplasia is a rare complication with poor prognosis after intensive chemotherapy for acute myeloid leukemia. We present a 14-year-old boy with acute myeloid leukemia (AML), was complicated by chemotherapy induced persistent aplasia and he was expired because of prolonged neutropenia and pulmonary Aspergilosis. In this review we explain causes of persistent post chemotherapy persistent aplasia and prevention of this phenomenon during treatment with consideration of minimal residual disease (MRD) and response to question about chemotherapy titration dose.

Author Biographies

  • Babak Abdolkarimi, Assistant Professor of Pediatric Hematology-Oncology, Lorestan University of Medical Sciences, Khoramabad, Iran

    Assistant Professor of Pediatric Hematology-Oncology, Lorestan University of Medical Sciences, Khoramabad, Iran  

  • Soheila Zareifar, Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran


    Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran

  • Mahdi Shahriari, Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran

    Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran

  • Mohamad Reza Bordbar, Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran

    Associate Professor of Pediatric Hematology-Oncology, Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran 

  • Ali Amanat, Assistant Professor of Pediatric infectious disease, Dr Alborzi Research center, Shiraz University of Medical Sciences, Shiraz, Iran


    Assistant Professor of Pediatric infectious disease, Dr Alborzi Research center, Shiraz University of Medical Sciences, Shiraz, Iran 

Downloads

Published

2021-05-10

Issue

Vol. 2 No. 3 (2021): Volume 2 Issue 3

Section

Articles